EGFR and non-small cell lung carcinoma: Although the presence of Kirsten murine sarcoma virus (KRAS) mutations predicts a failure of non‐small cell carcinoma (NSCLC) patients to benefit from epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) therapy it may be more sensitive to programmed combination therapy of programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) inhibitors + anti‐angiogenesis.